Tigecycline's Hepatic Metabolism Basics
Tigecycline, a glycylcycline antibiotic, undergoes extensive hepatic metabolism primarily via reduction in the liver, forming an N-methylureido metabolite (M1) and glucuronidation products. About 59% of the dose is metabolized, with minimal renal clearance (13-22% excreted unchanged in urine).[1][2] This heavy reliance on liver function directly shapes dosing adjustments.
Dosing Changes in Liver Impairment
In Child-Pugh C (severe) liver disease, the loading dose stays at 100 mg, but maintenance doses drop to 25 mg every 12 hours due to a 2-fold increase in tigecycline's half-life (from ~27 hours in healthy patients to ~52 hours) and higher systemic exposure.[3][4] For Child-Pugh A or B (mild/moderate impairment), no adjustment is needed, as AUC increases are minimal (23% and 43%, respectively).[1]
| Liver Impairment Level | Loading Dose | Maintenance Dose | Frequency |
|------------------------|--------------|------------------|-----------|
| None (healthy) | 100 mg | 50 mg | q12h |
| Child-Pugh A/B | 100 mg | 50 mg | q12h |
| Child-Pugh C | 100 mg | 25 mg | q12h |
Why Metabolism Drives These Adjustments
Reduced hepatic enzyme activity in liver disease slows tigecycline clearance, raising drug levels and toxicity risk (e.g., nausea, elevated liver enzymes). FDA labeling recommends monitoring and dose reduction in severe cases to maintain therapeutic levels without excess accumulation.[3] No hemodialysis adjustment is required due to low dialyzability.
Risks and Monitoring in Liver Patients
Higher exposure correlates with increased adverse events; studies show 2-3x nausea/vomiting rates in Child-Pugh C patients on full doses.[4] Clinicians track LFTs, avoid use in acute liver failure, and consider alternatives like non-hepatically cleared antibiotics (e.g., beta-lactams) for milder cases.
Clinical Trial Data on Liver Disease Patients
Phase 3 trials excluded Child-Pugh C patients, but pharmacokinetic studies in 66 cirrhotics confirmed dose tweaks. Efficacy holds in adjusted regimens for intra-abdominal infections, with MIC coverage preserved.[2][5]
Sources
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: DrugPatentWatch.com - Tigecycline Pharmacokinetics
[3]: FDA Label for Tygacil
[4]: Muralidharan et al., Antimicrob Agents Chemother (2005)
[5]: Stein et al., Clin Ther (2007)